From a clinical standpoint, these data indicate the clinical value of serum sclerostin as a screening biomarker of hypertension in patients at higher risk of developing PAD and those who may benefit from a timely diagnosis or a more aggressive preventive intervention. The gene discussed is SOST; the disease is peripheral arterial disease.